FDAsafety guidance77% confidence
FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mylan Labs; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA200465. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM.
Supporting Context
- Therapeutic area
- Oncology · Bone Health
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs